Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from KYORIN Pharmaceutical Co.,Ltd. ( (JP:4569) ) is now available.
KYORIN Pharmaceutical has entered into an option agreement with Cyrano Therapeutics to potentially license CYR-064, a novel treatment for post-viral hyposmia, in Japan. This agreement allows KYORIN to develop and commercialize the drug, which is currently in Phase 2 trials in the U.S., and aims to improve the quality of life for individuals suffering from olfactory dysfunction, a condition with no current effective treatments.
More about KYORIN Pharmaceutical Co.,Ltd.
KYORIN Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of high-value new drugs to meet medical needs. The company emphasizes open innovation as part of its long-term strategy Vision 110.
YTD Price Performance: -7.91%
Average Trading Volume: 85,681
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen79.42B
See more data about 4569 stock on TipRanks’ Stock Analysis page.